An ‘n-of-1’ placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris
Authors:
- 1 May 2009
- journal article
- case report
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 160 (5) , 1098-1102
Abstract
Pemphigus vulgaris (PV) is an organ-specific autoimmune blistering mucocutaneous disorder that is potentially fatal. High-dose intravenous immunoglobulin (IVIg) is increasingly used in the treatment of autoimmune diseases and it has been reported that it may also be effective in PV. To evaluate prospectively the efficacy of IVIg for PV using an 'n-of-1' placebo-controlled trial. A randomized, placebo-controlled, crossover trial of IVIg was conducted in a single patient with severe PV, comprising two phases of six consecutive months of either IVIg or placebo infusion. Before the commencement of the trial, the patient had received 18 months of IVIg but concerns about the continuing therapeutic efficacy of IVIg led to the double-blind placebo-controlled 'n-of-1' trial of IVIg. Pemphigus autoantibody titres were significantly higher when on placebo compared with IVIg treatment (median 1 : 80 vs. 1 : 20, P = 0.007), desmoglein 3 (126 vs. 79, P = 0.004) and desmoglein 1 antibody levels (126 vs. 94, P = 0.004). There was a significant improvement in subjective disease activity scores while on IVIg compared with placebo (mean overall score 11.6 vs. 20.6, P < 0.0001). The results of this study confirm a beneficial effect of IVIg in the management of refractory PV.Keywords
This publication has 12 references indexed in Scilit:
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008
- Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trialThe Lancet Neurology, 2008
- Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune GlobulinNew England Journal of Medicine, 2006
- The role of IVIg treatment in severe pemphigus vulgarisJournal of the European Academy of Dermatology and Venereology, 2006
- Clinical uses of intravenous immunoglobulinClinical and Experimental Immunology, 2005
- Effectiveness of Intravenous Immunoglobulin Therapy for Skin Disease Other Than Toxic Epidermal Necrolysis: A Retrospective Review of Mayo Clinic ExperienceMayo Clinic Proceedings, 2005
- Corticosteroid-Sparing Effect of Intravenous Immunoglobulin Therapy in Patients With Pemphigus VulgarisArchives of Dermatology, 2002
- Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatmentJournal of the American Academy of Dermatology, 2001
- Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpuraThe Lancet, 1994
- An "n of 1" trial of intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.Journal of Neurology, Neurosurgery & Psychiatry, 1994